Background:
Immune checkpoint inhibitors (ICIs) have transformed cancer care, yet immune-related adverse events involving the cardiovascular system, particularly myocarditis, remain among the most severe and life-threatening complications. While dual ICI regimens are known to increase cardiotoxic risk, the cardiovas...
N. Maurea, M. Passariello, Assunta Esposito et al.· Circulation· 0 citations
Cancer immunotherapy with immune checkpoint inhibitors (ICIs), i.e., antibodies targeting inhibitory ICs, such as PD-1, PD-L1, and CTLA-4, have successfully revolutionized cancer treatment. One of the most promising cancer immunotherapies is based on bi-specific T-cell engagers that simultaneously bind with one arm to...
M. Passariello, M. Belardo, Toshikazu Inoue et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.